 |
 |

Left Ventricular Hypertrophy Regression and Atrial Fibrillation Incidence
 |
 |
| Since this article does not have an abstract, we have provided the first 149 words of the full text and any section headings. |
|
 |
 |
To the Editor: In their study of patients with electrocardiographic left ventricular hypertrophy (LVH), Dr Okin and colleagues1 identify an association between LVH regression as measured by the Cornell product and decreased risk of atrial fibrillation. They cite a prior study2 of this simple and low-cost electrocardiographic measure that shows a correlation with LVH.
It would be helpful to know if the authors have any information indicating whether the correlation of the Cornell measure remains intact during a treatment maneuver compared with a test such as echocardiography that was not performed in their present study. In addition, because patients often ask about the time frame after initiating hypertensive treatment in which they can expect a regression of their newly diagnosed LVH, it would be useful if the authors could provide data on the mean or median time to LVH regression after initiation of the protocol.
Financial Disclosures: None reported.
Mark H. Hyman, MD
mark@hymanmd.net Department of Medicine University of California Los Angeles
1. Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296:1242-1248.
FREE FULL TEXT
2. Okin PM, Roman MJ, Devereux RB, et al. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;25:417-423.
ABSTRACT
JAMA. 2007;297:40.
RELATED LETTER
Left Ventricular Hypertrophy Regression and Atrial Fibrillation IncidenceReply
Peter M. Okin and Richard B. Devereux
JAMA. 2007;297(1):40-41.
EXTRACT
| FULL TEXT
|